Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18~* Histological or cytological diagnosis of adeno- or undifferentiated non-small cell carcinoma of pancreas.~* Considered to be unresectable based on following: extensive peri-pancreatic lymph node involvement, encasement or occlusion of the SMV or SMV/portal vein confluence, direct involvement of SMA, coeliac axis, inferior vena cava or aorta.~* Performance status 0-2~* No evidence of metastatic disease as determined by CT scan/ other investigations~* Adequate bone marrow function with platelets\>100\^9/l; WBC\>3x10\^9/l;neutrophils\> 1.5x10\^9/l~* Serum bilirubin ,1.5 x ULN and transaminases \< 2.5 x ULN~* Calculated/measured GFR \>50ml/min~* No concurrent uncontrolled medical condition~* No active malignant disease other than non-melanotic skin cancer or carcinoma in situ of the uterine cervix over the last 10 years~* Life expectancy \> 3months~* Adequate contraceptive precautions~* Informed written consent~Exclusion Criteria:~* medical or psychiatric conditions that compromise the patient's ability to give informed consent~* Presence of met. disease~* Concurrent uncontrolled medical conditions~* Any previous chemo/RT or any investigational treatment for advanced pancreatic cancer.~* Adjuvant chemo + fluoropyrimidine or gemcitabine within 12months of trial entry~* Adjuvant RT with/without chemo for pancreatic cancer.~* Pregnancy/breast feeding~* Patients with known malabsorption syndromes ro a lack of physical treatment of the upper GI tract.~* Patients with a known hypersensitivity to 5-FU or with a DPD deficiency.~* Clinically significant CVD

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): UFT/LV + RT
- Group 2 (Type: ACTIVE_COMPARATOR): UFT/LV + RT + Cetuximab

Based on this trial design, predict the completion outcome and termination type (if applicable).